Distribution: As Appendix 1

From: Chief Pharmaceutical Officer, Andrew Evans

Date: 9 November 2020

Reference: CEM//CPhA/2020/50a

Category: Important information for immediate action

Title: Publication Of A Revised Clinical Commissioning Policy: Remdesivir For Patients Hospitalised With Covid-19 (Adults And Children Aged 12 Years And Older)

For Action by:

> Chief Pharmacists - Action as below.
> Medical Directors – Action as below.

What is this about: Update to clinical commissioning policy for remdesivir.

Why has it been sent: For your information, action and to pass on to colleagues.

Issue:

Following confirmation of a Conditional Marketing Authorisation (CMA) by the European Medicines Agency (EMA), the use of remdesivir in the treatment of COVID-19 has been supported in the UK by an Early Access to Medicines Scheme (EAMS), implemented from 26th May 2020, and subsequently by an interim clinical commissioning policy, which has been in place since 3 July.

The clinical commissioning policy has now been updated to reflect the more positive position on remdesivir supply into the UK (via the European Union Joint Procurement Agreement arrangements) and to reflect the latest available evidence, including interim results from the Solidarity Therapeutics Trial coordinated by the World Health Organization.

The attached therapeutic alert and revised policy document provide further detail and highlight required actions:
- DHSC Covid 19 Therapeutic Alert CEM/CMO/2020/035 (6 November 2020)
- Interim Clinical Commissioning Policy: Remdesivir for patients hospitalised with COVID-19 (adults and children 12 years and older) Version 2 (6 November 2020)

This guidance supersedes CEM/CPhA/2020/46a issued 30 September 2020 *Update to CEM/CPhA/2020/42b- Remdesivir for patients hospitalised with Covid-19 (Adults and children aged 12 years and older)- Supply Disruption*

To: Health Boardsand NHS Trust

Chief Executives

Medical Directors

Nurse Directors

Directors of Public Health

Chief Pharmacists to action as per alert

NHS Direct